NASDAQ · BPMC
Healthcare · Biotechnology
$129.46
Up+$0.18 (+0.14%)
Updated Sep 10, 2026, 11:11 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BPMC does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning BPMC.
BPMC research
Company profile and research snapshot.
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 17, 2025 | Wells Fargo | Equal-Weight | — |
| Jun 5, 2025 | Morgan Stanley | Equal-Weight | — |
| Jun 5, 2025 | UBS | Neutral | — |
| Jun 4, 2025 | Citigroup | Neutral | — |
| Jun 3, 2025 | JMP Securities | Market Perform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jul 18, 2025
Sanofi has completed its acquisition of Blueprint Medicines for $129 per share, adding a rare immunology medicine (Ayvakit/Ayvakyt) and promising pipeline focused on systemic mastocytosis to its portfolio.
GlobeNewswire Inc. · Jul 18, 2025
Sanofi completed the acquisition of Blueprint Medicines on July 18, 2025, adding specialized immunological rare disease treatments and medications targeting mastocytosis to its portfolio for $129 per share.
GlobeNewswire Inc. · Jul 17, 2025
Sanofi has extended its tender offer to purchase Blueprint Medicines Corporation shares at $129.00 per share, with approximately 45.85% of shares already tendered. The offer is now set to expire on July 17, 2025.
GlobeNewswire Inc. · Jul 17, 2025
Sanofi has extended its public tender offer to acquire Blueprint Medicines Corporation, with the offer now expiring on July 17, 2025. Approximately 45.85% of Blueprint's outstanding shares have been validly tendered, with an additional 36.08% submitted via guaranteed delivery notice.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BPMC.
No results
No recent SID articles mention BPMC.
